ASCO26: RevMed’s daraxonrasib presents a turning point for pancreatic cancer - Clinical Trials Arena
ASCO26: RevMed’s daraxonrasib presents a turning point for pancreatic cancer Clinical Trials ArenaDaily pill doubles survival time for pancreatic cancer patients BBC‘Landmark’ pancreatic cancer drug keeps patients alive for twice as long The Washington PostDaily pill can double survival time for world’s deadliest cancer, trial shows | Pancreas cancer The GuardianStanding ovation at ASCO 2026: Daraxonrasib Shines in Pancreatic Cancer Breakthrough Medical Dialogues
